ReviewFrontiers in chemistry2021
Nanozymes Regulate Redox Homeostasis in ROS-Related Inflammation.
Review in Frontiers in chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Engineering nanozymes for cancer theranostics: Chemical design, catalytic intelligence, and translational oncology frontiers.Translational oncology · 2026Review
- Metal-Functionalized Nanozymes in Antibacterial Wound Management: Recent Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Oxidative stress and reactive oxygen species in otorhinolaryngological diseases: insights from pathophysiology to targeted antioxidant therapies.Redox report : communications in free radical research · 2025Review
- Ethyl Acetate Extract ofCurrent issues in molecular biology · 2025Article
- Nanomedicine in cardiovascular and cerebrovascular diseases: targeted nanozyme therapies and their clinical potential and current challenges.Journal of nanobiotechnology · 2025Review
- Article
- Is periodontitis triggering an inflammatory response in the liver, and does this reaction entail oxidative stress?Odontology · 2025Review
- Nanozyme-based visual diagnosis and therapeutics for myocardial infarction: The application and strategy.Journal of advanced research · 2025Review
- Nanozymes for Treating Ocular Diseases.Advanced healthcare materials · 2025Review
- Removing Barriers to Tumor 'Oxygenation': Depleting Glutathione Nanozymes in Cancer Therapy.International journal of nanomedicine · 2025Review
- Bioactive Components of Areca Nut: An Overview of Their Positive Impacts Targeting Different Organs.Nutrients · 2024Review
- Alleviation effects of epigallocatechin-3-gallate against acute kidney injury following severe burns.Clinical and experimental nephrology · 2024Article
- Exploring the Effect and Mechanism of DaYuan Yin Against Acute Lung Injury by Network Pharmacology, Molecular Docking, and Experimental Validation.Drug design, development and therapy · 2024Article
- A novel degradable PEG superparamagnetic iron oxide capsule coupled with a polyphenolic nano-enzymatic conjugate (PSPM-NE), to treat ROS-driven cardiovascular-diseases, tested in atherosclerosis as a model disease, and hypothesizing autoimmunity as an atheroma's trigger.Frontiers in cardiovascular medicine · 2024Article
- Pleiotropic Potential ofMolecules (Basel, Switzerland) · 2023Article
- Hydrogenated silicene nanosheet functionalized scaffold enables immuno-bone remodeling.Exploration (Beijing, China) · 2023Article
- Melatonin reduces IL-33 and TSLP expression in human nasal epithelial cells by scavenging ROS directly.Immunity, inflammation and disease · 2023Article
- Tri-element nanozyme PtCuSe as an ingenious cascade catalytic machine for the amelioration of Parkinson's disease-like symptoms.Frontiers in bioengineering and biotechnology · 2023Article
- Role of oxidative stress in the relationship between periodontitis and systemic diseases.Frontiers in physiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS), in moderate amounts, play an essential role in regulating different physiological functions in organisms. However, increased amounts of ROS may cause oxidative stress and damage to biomolecules, leading to a variety of diseases including inflammation and even cancer. Therefore, ROS scavenging reagents are needed to maintain healthy levels of ROS. With considerable advances in nanotechnology, nanozymes possess SOD or CAT-like activities with outstanding free radical scavenging activity, facile synthesis conditions, and excellent biocompatibility. Based on these extraordinary properties, nanozymes has been used to modulate the redox homeostasis and relieve the ROS-related injury. This has led to the emergence of nanozyme-based therapies. In the current review, we presented recently developed applications of nanozymes to treat ROS-dependent disorders with an emphasis on inflammatory and brain diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.